Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GLP-1, Weight loss
Weight-loss drugs didn't curb health costs within two years
Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.
More state Medicaid programs consider covering GLP-1 drugs
While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs for obesity. Currently, just 13 state Medicaid programs cover GLP-1s for obesity. Most of the states that don’t cite the drugs’ high cost.
Weight-loss surgeries decline 25% as GLP-1 drugs grow in popularity
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.
US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health programs for low income people, citing cost as a key factor, according to a survey conducted by health research firm KFF.
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
For Most GLP-1 Users, Taking Prescription Weight-Loss Drugs Comes With a Social Stigma
This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The pool is wide for the weight-loss industry in the United States. At present, CivicScience data indicate that two-thirds of U.
Ozempic and other weight loss drugs aren't lowering health care costs yet
GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according to a new analysis of U.S. health insurance claims.
Study finds high costs, few benefits associated with GLP-1 weight loss drugs
A new study from a pharmacy benefit manager is casting doubt on the benefits of GLP-1 drugs used for weight loss, finding they are associated with a high cost of care with little benefit beyond dropping pounds.
17h
on MSN
Bariatric surgeries drop sharply as people turn to Wegovy, Saxenda for weight loss
The demand for bariatric operations dropped sharply last year as use of anti-obesity drugs such as Wegovy surged, study finds ...
2d
Taylor bikes 55 miles at 50 with Dr. Kell’s Program
Looking for a weight loss program that can truly transform your life? Dr. Kells’ Weight Loss program might be just what you ...
Rolling Out
2d
The truth about detox diets
The wellness industry frequently promotes detox diets as miracle solutions for weight loss, improved health, and body ...
4d
Where Do You Lose Weight First?
Face, stomach, hips, legs. No, it’s not a new dance routine. Instead, it’s what might be going through your mind when trying ...
KSL
2d
Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback